Global Acromegaly and Gigantism Drugs Market 2018-2022

Below are some of the key findings from the acromegaly and gigantism drugs market research report

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global acromegaly and gigantism drugs industry overview

The presence of a strong pipeline will be one of the primary factors driving the acromegaly and gigantism drugs market growth until 2022. Researchers are focusing on launching pipeline molecules for acromegaly and gigantism and most of these molecules are in the Phase III stage of development. The availability of a large number of molecules in the pipeline is resulting in increased consumption of gigantism and acromegaly drugs. Numerous companies are trying to meet the medical needs for this condition by focusing more on drug development. Pasireotide long-acting release (LAR) by Novartis and octreotide capsules by Chiasma are in the Phase III stage of development for the treatment of acromegaly. They are targeted at individuals with acromegaly who are inadequately treated with the combination therapy of lanreotide autogel and pegvisomant by Ipsen and somatostatin analogs. This, in turn, results in a strong pipeline for gigantism and acromegaly treatment. Based on the acromegaly and gigantism drugs market insights, this market will register a CAGR of about 3% during the forecast period. 

The demand for non-surgical options and the popularity of pharmacological therapies for acromegaly treatment is increasing on a regular basis due to the low success rate of acromegaly surgeries. According to our analysts, this is one of the key trends that will stimulate the growth of the acromegaly and gigantism drugs market size and share. It has been observed that only four of the 31 subjects treated by trans-sphenoidal surgery were cured. Additionally, post-operative anterior pituitary hormone deficiency was also observed in about 10 subjects. The preference of drug therapies for treating the disease will continue to increase due to the lack of skilled surgeons and pituitary surgical centers.

Top acromegaly and gigantism drugs companies covered in this market research report

The acromegaly and gigantism drugs market is moderately fragmented with companies focusing on developing new drugs. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, this acromegaly and gigantism drugs industry analysis report is designed to aid clients identify new growth opportunities and design innovative strategies for strengthening their position in the market.

The report offers a complete analysis of various companies including:

• Ipsen
• Novartis
• Pfizer

Acromegaly and gigantism drugs market segmentation based on geographic regions

• Americas
• APAC
• EMEA

The Americas will account for the highest market share throughout the forecast period. The Americas has always been a key market in the context of global acromegaly and gigantism drugs demand and this is mainly due to the high prevalence of the disease in the region.

Acromegaly and gigantism drugs market segmentation based on drug class

• Somatostatin analogs
• GH receptor antagonists
• Dopamine agonists
• Recombinant human IGF-1

The somatostatin analogs segment will account for the highest growth in the market. Additionally, the report will also provide an accurate prediction of the contribution of the various drug class segments to the growth of the acromegaly and gigantism drugs market size.

Key highlights of the global acromegaly and gigantism drugs market for the forecast years 2018-2022:

• CAGR of the market during the forecast period 2018-2022
• Detailed information on factors that will accelerate the growth of the acromegaly and gigantism drugs market during the next five years
• Precise estimation of the global acromegaly and gigantism drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• Growth of the acromegaly and gigantism drugs industry across the Americas, APAC, and EMEA
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details on the factors that will challenge the growth of the acromegaly and gigantism drugs companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch